evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

539 questions · 553 findings · 58 reviews · Airways

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 37 · 6.7%GRADE not reported 8 · 1.4%Very low 27 · 4.9%Low 161 · 29.1%Moderate 219 · 39.6%High 101 · 18.3%

Benralizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Benralizumab subcutaneous (SC) leads to higher clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Mepolizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab intravenous (IV) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Mepolizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab intravenous (IV) vs placebo

Rate of exacerbations requiring emergency department treatment or admission · people with asthma

Mepolizumab intravenous (IV) leads to lower rate of exacerbations requiring emergency department treatment or… compared with placebo (high certainty).

1 finding from 1 review

14 days on/off antibiotic regimen vs 14 days on/off placebo regimen

Exacerbation frequency · people with bronchiectasis

14 days on/off antibiotic regimen probably leads to lower exacerbation frequency compared with 14 days on/off placebo regimen (moderate certainty).

2 findings from 1 review

28 days on/off antibiotic regimen vs 28 days on/off placebo regimen

Pulmonary exacerbations: number of hospitalisations due to respiratory exacerbations · people with bronchiectasis

28 days on/off antibiotic regimen showed no clear difference in hospitalisation for pulmonary exacerbations compared with 28 days on/off placebo regimen (high certainty).

1 finding from 1 review